Delårsrapport Q2 2021: Vellykket CoreBuild-opkøb påvirker tallene positivt
August 10, 2021 03:26 ET
|
WirTek A/S
Selskabsmeddelelse nr. 14/2021 Bestyrelsen for Wirtek A/S har i dag behandlet og godkendt delårsrapporten for Q2 2021. Delårsrapporten er i sin helhed vedhæftet denne selskabsmeddelelse. CEO...
Jotul Holdings SA - Financial report for the period from 1 January to 31 March 2021
May 28, 2021 07:00 ET
|
Jøtul AS
YTD Q1 2021, the Jotul Group reached a consolidated profit of MNOK -10.1 (Q1 2020: MNOK -25.3). The operating result totaled MNOK 7.3 in YTD Q1 2021 (Q1 2020: MNOK -45,2). The total comprehensive...
Jotul Holdings S.A - Interim report Q4 - 31. december 2020
February 26, 2021 07:00 ET
|
Jøtul AS
YTD Q4 2020, the Jotul Group reached a consolidated profit of MNOK -128.9 (Q4 2019: MNOK -86.8). The operating result totaled MNOK -66.7 in YTD Q4 2020 (Q4 2019: MNOK 27.3). The 2020 total...
JØTUL HOLDINGS SA - INTERIM REPORT Q3 - 30. SEPTEMBER 2020
November 27, 2020 07:00 ET
|
Jøtul AS
YTD Q3 2020, the Jotul Group reached a consolidated profit of MNOK -123 (Q3 2019: MNOK -46.3). The operating result totaled MNOK -72.9. YTD Q3 2020 (Q3 2019: MNOK 0). The 2020 total comprehensive loss...
Jotul Holdings S.A. - Statement on Interim Financial Report for the half-year ended 30 June 2020
November 13, 2020 07:00 ET
|
Jøtul AS
Jotul Holdings S.A. (the “Company”) hereby refers to the Interim Financial Report for the halfyear ended 30 June 2020 (the “Interim Report”) as published on 6 November 2020. The Company further...
Jotul Holdings SA Interim financial report - Half-year ended 30 June 2020
November 06, 2020 07:00 ET
|
Jøtul AS
In the first half of 2020, the Jotul Group reached a consolidated profit of MNOK -68.5 (H12019: MNOK -46.9). The operating result totaled MNOK -60.1 in H1 2020 (H1 2019: MNOK -16.7). The 2020 total...
Zealand Pharma announces acceleration of U.S. commercial operations through the completion of the Valeritas acquisition; FDA acceptance of New Drug Application submission for the dasiglucagon HypoPal® rescue pen; pipeline progress including
August 13, 2020 09:00 ET
|
Zealand Pharma
Interim report for H1 2020 Zealand Pharma announces acceleration of U.S. commercial operations through the completion of the Valeritas acquisition; FDA acceptance of New Drug Application...
Zealand Pharma files New Drug Application with U.S. FDA for dasiglucagon HypoPal® rescue pen, secures DKK 137 million in additional investment, and accelerates readiness of U.S. commercial operations: Interim report for Q1 2020
May 14, 2020 09:00 ET
|
Zealand Pharma
Zealand Pharma files New Drug Application with U.S. FDA for dasiglucagon HypoPal® rescue pen, secures DKK 137 million in additional investment, and accelerates readiness of U.S. commercial operations ...
Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019
October 28, 2019 12:00 ET
|
Zealand Pharma
Press Release – No. 20 / 2019 Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019 Copenhagen, October 28, 2019 – Zealand Pharma A/S...
Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commercial build-up in the U.S.
August 15, 2019 09:00 ET
|
Zealand Pharma
Company announcement – No. 25 / 2019 Zealand Pharma delivers strong clinical results during the first half of 2019 and accelerates commercial build-up in the U.S. Copenhagen, August 15, 2019 –...